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fractionation was not significant for both TNM and TRG (p > 
0.100). Among dosimetric parameters, Dmin resulted 
statistically different depending on the patient T staging 
variation (p < 0.005). Specifically, focusing on the 21 patients 
with favourable pathological response, significant correlation 
was found with the T index variation (ρSpearman = -0.667, p 
= 0.001), with higher Dmin related to patients undergoing 
total remission. No other dosimetric parameters resulted 
associated with clinical tumor regression outcomes.  
 
Conclusion: In this series we found a statistically significant 
correlation between T staging regression and the Dmin to the 
PTV. Patients with partial or complete pathological response 
showed a higher Dmin when compared to patients with no 
change in TNM staging. Further studies are needed to 
understand if there is any relation between the site of 
underdosages and the tumor site.  
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Purpose or Objective: The standard treatment for locally 
advanced rectal cancer (LARC) is neoadjuvant chemo-
radiation (CRT) followed by mesorectal excision. However, 
surgical specimen histopathology demonstrates a complete 
pathological response (pCR) in almost 30% of cases. In 
consequence, these patients (pts) may benefit from 
conservative management.  
The aim of this study is to evaluate the role of 18F-FDG-
PET/CT in pts with LARC in the prediction of pCR after 
treatment with CRT. 
 
Material and Methods: From September 2009 to May 2014, 39 
pts (mean age: 62 years, range 40-83) with LARC underwent 
18F-FDG-PET/CT for staging and radiotherapy (RT) treatment 
planning. Tumour location within rectum: superior: 17 
(43.85%); middle: 14 (35.89%); inferior: 8 (20.51%). Histology: 
adenocarcinoma: 37 (94.87%); mucinous adenocarcinoma: 2 
(5.13%). Tumour staging: II: 7 (17.95%); III: 31 (79.48%); IV 
(resected liver metastases disease): 1 (2.56%).  
All pts received conformal RT (Nodal PTV: 4500 cGy, Tumor 
PTV: 5040 cGy) with concurrent Capecitabine, before 
undergoing either low anterior resection (32pts-82.05%) or 
abdomino-perineal resection (7pts-17.95%).  
The tumour regression grade (TRG) according to Mandard´s 
criteria was assessed by the pathologist. Pts were classified 
into two groups: responders (TRG 1 and 2) and non-
responders (TRG 3 to 5). The TRG was correlated with 18F-
FDG-PET/CT parameters (tumour volume, tumour SUVmax 
and nodal SUVmax). 
 
Results: Following CRT, 7/39 pts (17.94%) showed no 
evidence of residual tumour in the surgical specimen (pCR). 
By TRG status, 14 pts (35.9%) were classified as responders 
and 25 (64.10%) as non-responders. When analyzing 18F-FDG-
PET/CT parameters, no significant difference was found 
between responders and non-responders for: tumour volume 
(mean: 5.84cm3 vs 6.24 cm3, p=0.35); tumour SUVmax (21.95 
vs 20.73, p=0.61); nodal SUVmax (4.73 vs 7.56, p=0.12) or 
staging (6.71 vs 7.56, p=0.23). Histopathological responders 
had better overall survival compared to non-responders, 
however this was not statistically significant (617 vs 269 days, 
p=0.37).  
 
Conclusion: In our cohort, 18F-FDG-PET/CT parameters 
cannot predict the tumour response to CRT. Nevertheless, 
higher levels of SUVmax and bigger tumour volumes are found 
in the non-responders group and also worst overall survival. 
Stronger conclusions should be established in this matter in 
order to select patients for an organ-preservation safely.  
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Purpose or Objective: The approach to patients with lung 
metastasis from primary colon-rectal cancer is based on 
systemic therapy and the role of stereotactic body 
radiotherapy (SBRT) is still to be investigated. The present 
work aims to study the impact of SBRT in oligometastatic 
patients with lung metastasis from colon-rectal cancer. 
 
Material and Methods: From May 2010 to March 2015, 33 
consecutive patients (median age 66 years, range 31-88) with 
lung metastasis from colon-rectal cancer were treated with 
SBRT. All patients were treated using Image Guided 
Radiotherapy (IGRT) and stratified according to K-RAS and B-
RAF genotype. The systemic progression free survival and 
local control were the primary and secondary endpoint 
evaluated respectively. 
 
Results: A total of 56 active lesions were treated. After a 
median follow-up of 12.6 months, median OS was 10.5 
months. The radiotherapy dose delivered and the schedule 
adopted were 24-27 Gy as a single fraction and 27-42 Gy/3 
fractions. Nineteen out of 33 patients were affected by rectal 
cancer while 14 patients by colon cancer. Median Planning 
Target Volume value was 21.45 cc (range 6-156). Mean local 
relapse was recorded in 23 lesions (41.1%) at a median 
interval of 19.3 months (range 5-37). By the way, 23 out 33 
patients (69.7%) experienced systemic progression after a 
mean time of 12.6 months (1-24) from SBRT. No differences 
of local or systemic control were observed considering K-RAS 
and B-RAS genotype. Severe toxicity were not recorded.  
 
Conclusion: The results of this study suggest that SBRT could 
represent a safe and valid approach to oligometastatic 
patients with lung metastasis from colon-rectal cancer. 
However, further studies are needed in order to better 
characterize patients potentially suitable for SBRT. 
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Purpose or Objective: The purpose of our study is to report 
on the acute toxicity and response to treatment in patients 
affected by squamous cell anal carcinoma (SCAC) that 
underwent tomotherapy (TO) at 2 institutions.  
 
Material and Methods: A cohort of 39 patients affected by 
SCAC and treated with TO between December 2009 and July 
2015 was retrospectively analyzed. Concurrent chemotherapy 
(CT) was always administered except in patients unfit for 
intensive therapy due to comorbidity and/or with early stage 
disease (T1-T2N0). The choice of CT regimen was left to the 
discretion of the treating institution, as well as the IMRT 
schedule adopted. The dose/fractionation prescribed to PTV1 
(high-risk volume), PTV2 (intermediate-risk volume) and PTV3 
(low-risk volume) ranged between 66– 50 Gy, 50.4 – 45 Gy 
and 46.2 – 36 Gy, respectively, at a corresponding dose per 
fraction range of 2.2 – 1.8 Gy for PTV1, 2 – 1.67 Gy for PTV2, 
and 1.65 – 1.5 Gy for PTV3, delivered in a range of 25-33 
daily fractions. Acute toxicity was scored according to NCI – 
CTCAE v.4. Response was assessed at 12 weeks after the end 
of treatment via digital rectal exam and anoscope. 
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Morphologic and/or metabolic imaging re-assessment was 
performed between 12 and 26 weeks after treatment. 
Disease-free survival (DFS) was calculated from the end of 
treatment to the date of first event of disease recurrence. 
Overall survival (OS) was calculated from the end of 
treatment to the date of death from any cause or of last 
follow-up. 
 
Results: All patients are evaluable for acute toxicity 
assessment while clinical outcome has been analyzed in 
29/37 (79,4%) patients, with a median follow-up of 8 months 
(range 3-69). Baseline clinical features of the whole cohort 
are summarized in table 1. Concurrent CT was given in 30 
patients (81.1%) and in 23 of them (76.6%) the preferred 
regimen consisted of 5 – fluoruracil – mitomycin C 
combination. A sequential IMRT schedule was delivered in 9 
patients (24.3%) while 28 (75.7%) underwent IMRT-SIB. In 22 
patients (60%) treatment was completed without any 
interruptions while the median duration of treatment breaks 
was 7 days (range 1-16) in the remaining group. In terms of 
acute toxicity, the rate of G3+ diarrhea and dermatitis was 
8.1% and 13.5%, respectively. No G3+ GU and hematological 
toxicities were reported. Complete response was achieved in 
21/29 patients (72.4%), partial response/stable disease in 7 
(24.1%) and local disease progression in 1 (3%). All patients 
were alive at last follow-up. The 1-year OS, DFS, and 
colostomy-free survival were 100%, 85%and 96%, respectively.  
 
 
 
 
Conclusion: In our dual institution experience, concurrent 
chemo-radiation with TO for SCAC was associated with a 
favorable acute toxicity profile, in line with published 
experiences. Considering the prevalence of very advanced 
loco-regional disease in our cohort, early response 
assessment is noteworthy, although a longer follow-up is 
needed to confirm the long-term benefit and to evaluate the 
incidence of late toxicity.  
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Purpose or Objective: To report the clinical results of six 
years experience with Adaptive Radiotherapy concomitant 
with chemotherapy in the preoperative treatment of rectal 
cancer. 
 
Material and Methods: Patients (pts) with T3/T4N0 or any 
TN+ rectal adenocarcinoma were enrolled in an observational 
trial. Chemotherapy consisted of Oxaliplatin 100mg/m2 on 
the days -14, 0, +14, and continuous infusion 5-FU 
200mg/m2/day from day -14 to the end of radiotherapy. 
Concomitant Radiotherapy (RT) started on the day 0, was 
delivered with Tomotherapy, and consisted of 41.4 Gy in 18 
fractions (frs) (2.3 Gy/fr) to the PTV defined as CTV, the 
tumor and regional lymph-nodes contoured on the initial 
simulation CT and MRI, with a margin of 0.5 cm. Simulation 
CT and MRI were repeated after two cycles of chemotherapy 
and 9 frs of RT for the planning of the adaptive RT phase: 
